Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
Non-invasive ultrasound procedure, Ultherapy, to now lift and tighten skin on the chest
MESA, Ariz., -- Ulthera, Inc. - a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology - today announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area - also known as the decolletage or decollete.
The Ulthera System - which combines time-honored ultrasound imaging with focused ultrasound therapy in a procedure known as Ultherapy - has been used in many Asian countries to treat the face and neck since 2008. The new decolletage indication will utilize the System's same technology to encourage the natural formation of collagen and elastin on the chest - just as with the face and neck - giving it the ability to lift tissue. For the decolletage, this lifting effect can result in a gradual reduction of chest wrinkles over three months, with continued improvement possible for up to six months post-procedure.
"The global demand for safe and effective non-invasive procedures is rapidly growing. This is why Ulthera has made significant investments in clinical development to qualify our ultrasound platform technology for a host of medical and off-face aesthetic indications," said Matthew Likens, president and CEO of Ulthera. "Launching the decolletage treatment in Asia is just the tip of the iceberg. We anticipate an exciting second half of 2012 with even more international indications on the horizon as well as additional countries where System clearance is anticipated."
Starting July 3, 2012, Ulthera will be initiating a multi-country tour in Asia to introduce the new clinical indication to practitioners. For more information on the tour, contact Candice Wong at firstname.lastname@example.org or +852-9650-1505.
The Ulthera System is cleared by the U.S. FDA for use in a non-invasive treatment of the face to lift the eyebrow to achieve a desired aesthetic effect. The new clinical indication to treat the decolletage will not be commercially available in all Asian countries, including those that do not currently offer Ultherapy as well as Singapore and Hong Kong where the System is only cleared to treat the face.
Ulthera, Inc. is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® - the procedure enabled by the System - is a non-invasive treatment of the face to achieve a brow lift. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.
CONTACT: Susan Sorensen, Ulthera, Inc., +1-480-619-4069, email@example.com
Web Site: www.ultherapy.com